Expanded access to dupilumab for severe food allergy
Treatments studied
Part of Immune system & allergy clinical trials.
This program provides continued access to dupilumab, an injectable medication that may help reduce severe allergic reactions to food, for adults who previously completed a related study. It is designed for those who tolerated the treatment well and need ongoing therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult who completed the final visit in the earlier study of this medication.
- You did not have a serious side effect during the earlier study that would make this unsafe.
- You did not need to pause the medication for more than 2 weeks during the earlier study.
- You received your last dose of the study medication within the last 2 weeks.
- Your doctor confirms you meet any other study requirements.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well dupilumab works for children and teens with severe eczema (atopic dermatitis) even when the rash is not widespread. It aims to see if the treatment helps with itching, quality of life, and rashes in visible or sensitive areas.
This study looks at how well Dupilumab works over time in people aged 12 and older with eosinophilic esophagitis (EoE) whose symptoms are not well controlled by standard treatments. It aims to understand the medicine's effects in everyday medical practice.
This program provides access to an experimental medication called dupilumab for people with serious conditions when no other treatments have worked. It is not a regular clinical trial, but a special access program for patients who have no other options.
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
This trial tests if dupilumab can help young children with eosinophilic esophagitis (EoE), a condition that causes swelling in the esophagus. It may reduce symptoms and improve how the esophagus heals.
This trial studies how the body’s “molecular signals” change in the skin after using dupilumab for eczema. It may help researchers understand who benefits most from treatment.
Hear when a new Food Allergy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.